-
公开(公告)号：US20090209464A1
公开(公告)日：2009-08-20
申请号：US12229436
申请日：2008-08-22
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , C12N2770/24022 , C12N2770/24122 , C12N2770/24222 , C12N2770/24322 , C12N2770/36122 , Y02A50/394
摘要： The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses.
摘要翻译： 本发明涉及抑制黄病毒病毒粒子与目标细胞膜之间的融合的肽和方法，其将病毒基因组递送到细胞质中。 本发明提供了使用肽或肽衍生物抑制黄病毒：细胞融合的方法。 本发明部分地基于以下发现：瘟病毒的HCV病毒的E1包膜糖蛋白和E2包膜糖蛋白具有先前未被描述的结构，截短的II类融合蛋白。 本发明提供治疗和预防由黄病毒引起的疾病的肽和方法。
-
公开(公告)号：US07854937B2
公开(公告)日：2010-12-21
申请号：US12229436
申请日：2008-08-22
IPC分类号： A61K39/12
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , C12N2770/24022 , C12N2770/24122 , C12N2770/24222 , C12N2770/24322 , C12N2770/36122 , Y02A50/394
摘要： The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses.
摘要翻译： 本发明涉及抑制黄病毒病毒粒子与目标细胞膜之间的融合的肽和方法，其将病毒基因组递送到细胞质中。 本发明提供了使用肽或肽衍生物抑制黄病毒：细胞融合的方法。 本发明部分地基于以下发现：瘟病毒的HCV病毒的E1包膜糖蛋白和E2包膜糖蛋白具有先前未被描述的结构，截短的II类融合蛋白。 本发明提供治疗和预防由黄病毒引起的疾病的肽和方法。
-
公开(公告)号：US08153360B2
公开(公告)日：2012-04-10
申请号：US12956460
申请日：2010-11-30
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , C12N2770/24022 , C12N2770/24122 , C12N2770/24222 , C12N2770/24322 , C12N2770/36122 , Y02A50/394
摘要： The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided.
摘要翻译： 本发明提供了具有选自SEQ ID NO：1至SEQ ID NO：36的氨基酸序列的分离的肽，以及包含各种N-末端和C-末端化学部分的衍生物，其取代的类似物 ，及其片段。 本发明的肽可用于治疗和预防黄病毒感染。 还提供了包含肽的药物组合物，以及治疗或预防黄病毒感染的方法。
-
公开(公告)号：US07416733B2
公开(公告)日：2008-08-26
申请号：US10532480
申请日：2003-11-07
申请人： Robert F. Garry , Srikanta Dash , David H. Coy , Jane A McKeating
发明人： Robert F. Garry , Srikanta Dash , David H. Coy , Jane A McKeating
IPC分类号： A61K39/12
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , C12N2770/24022 , C12N2770/24122 , C12N2770/24222 , C12N2770/24322 , C12N2770/36122 , Y02A50/394
摘要： The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses.
摘要翻译： 本发明涉及抑制黄病毒病毒粒子与目标细胞膜之间的融合的肽和方法，其将病毒基因组递送到细胞质中。 本发明提供了使用肽或肽衍生物抑制黄病毒：细胞融合的方法。 本发明部分地基于以下发现：瘟病毒的HCV病毒的E1包膜糖蛋白和E2包膜糖蛋白具有先前未被描述的结构，截短的II类融合蛋白。 本发明提供治疗和预防由黄病毒引起的疾病的肽和方法。
-
5.发明授权
公开(公告)号：US5567805A
公开(公告)日：1996-10-22
申请号：US302228
申请日：1994-09-07
IPC分类号： A61K38/00 , C07K14/16 , C07K14/705 , C07K14/435
CPC分类号： C07K14/005 , C07K14/705 , A61K38/00 , C12N2740/16122
摘要： The present invention relates to methods of inhibiting HIV-mediated cell killing which comprises inhibiting the interaction between the CS3 region and viral gp41 and its receptor on the surface of lymphocytes. The invention provides for methods which employ peptides, peptide derivatives, or antibodies to inhibit the CS3/CS3 receptor interaction. In addition, the invention also relates to the CS3 receptor.The present invention is based in part on the discovery that a CS3 specific cellular receptor is widely distributed on human lymphocytes and forms a 108 kd complex with CS3-HSA peptide conjugate. It was further discovered that CS3 peptide effectively blocks HIV mediated cell infection and killing. Therefore, the present invention provides for methods of treatment and prophylaxis of HIV infection as well as a means for better understanding the physiology of acquired immunodeficiency syndrome (AIDS).
摘要翻译： 本发明涉及抑制HIV介导的细胞杀伤的方法，其包括抑制CS3区域和病毒gp41及其淋巴细胞表面受体之间的相互作用。 本发明提供了使用肽，肽衍生物或抗体来抑制CS3 / CS3受体相互作用的方法。 此外，本发明还涉及CS3受体。 本发明部分基于CS3特异性细胞受体广泛分布在人淋巴细胞上并与CS3-HSA肽缀合物形成108kd复合物的发现。 进一步发现CS3肽有效阻断HIV介导的细胞感染和杀伤。 因此，本发明提供了治疗和预防HIV感染的方法以及更好地了解获得性免疫缺陷综合征（AIDS）的生理学的方法。
-
6.发明授权Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use 有权垂体腺苷酸环化酶活化多肽（PACAP）的类似物及其使用方法公开(公告)号：US08916517B2
公开(公告)日：2014-12-23
申请号：US13505370
申请日：2010-11-02
申请人： David H. Coy , Jerome L. Maderdrut , Min Li
发明人： David H. Coy , Jerome L. Maderdrut , Min Li
IPC分类号： A61K38/17 , C07K14/435 , A61P11/00 , A61P13/12 , A61P1/00 , A61P27/02 , A61P37/06 , A61P9/00 , A61P9/12 , A61P35/00 , A61P3/04 , A61P3/10 , A61K45/06 , C07K14/575 , A61K33/24 , A61K38/00
CPC分类号： C07K14/57563 , A61K33/24 , A61K38/00 , A61K38/2278 , A61K45/06 , A61K47/64 , A61K51/088 , A61L31/08 , A61L31/16 , A61L2300/252 , A61L2300/40 , A61L2420/00 , C07K2319/50 , A61K2300/00
摘要： This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
摘要翻译： 本发明涉及垂体腺苷酸环化酶活化多肽（PACAP）的新型类似物，其是PACAP /血管活性肠肽（VIP）受体的激动剂：PAC1，VPAC1和VPAC2受体。 这些PACAP类似物可以用作广泛的医学疾病的预防/治疗剂，包括（但不限于）癌症和自身免疫性疾病。 这些PACAP类似物可以耦合到合适的放射性核素，并用于弥散性癌症和转移性肿瘤的定位，诊断和治疗，或与小分子治疗剂偶联，并用作靶向药物递送的载体。 本发明还提供单独一种或与一种或多种其它预防/治疗剂组合的本发明的一种或多种PACAP样化合物的药物组合物。
-
7.发明授权Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof 有权抑制生长素释放肽/生长激素分泌受体途径及其用途的方法公开(公告)号：US08883721B2
公开(公告)日：2014-11-11
申请号：US13320408
申请日：2010-05-12
IPC分类号： A61K38/08 , A61K38/10 , C07K7/06 , C07K7/08 , A61K31/00 , A61K45/06 , A61K31/404 , A61K38/16 , A61K38/25
CPC分类号： A61K38/08 , A61K31/00 , A61K31/404 , A61K38/10 , A61K38/16 , A61K38/25 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.
摘要翻译： 本发明通过向受试者施用生长素释放肽O-酰基转移酶（GOAT）抑制剂和/或生长素释放肽受体拮抗剂来提供治疗，预防或控制受试者中肥胖症，肥胖相关病症，糖尿病和代谢综合征的方法。 本发明还提供式（VII）的生长素释放肽受体拮抗剂：A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18（SEQ ID NO：93），其中A11，A12 ，并且A13独立地不存在，氨基酸或氨基保护基; A15，A16，A17和A18各自独立地不存在或氨基酸; 并且A14是与-C（O）C1-C20烷基共轭的 - （O）C1-C20烷基或二氨基丙酸缀合的丝氨酸，条件是存在A11，A12或A13中的至少一种。
-
8.发明授权Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof 有权生长激素释放肽/生长激素释放肽/生长激素分泌受体拮抗剂及其用途公开(公告)号：US08536120B2
公开(公告)日：2013-09-17
申请号：US12298826
申请日：2007-04-30
IPC分类号： A61K31/15 , A61K31/216 , A61K38/08 , C07K7/06
CPC分类号： C07C233/75 , A61K38/00 , C07K7/02 , C07K7/06 , C07K14/60
摘要： The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.
摘要翻译： 本发明提供已被证明是生长素释放肽受体（生长激素促分泌素受体，GHS-R1a和亚型，其形式和变体）的调节剂的新化合物。 这些化合物可用作生长素释放肽受体的拮抗剂以及反向激动剂，部分激动剂或这些活性的组合，作为治疗和预防一系列医学病症的药物，包括但不限于代谢和/或内分泌疾病， 胃肠道疾病，心血管疾病，肥胖和肥胖相关疾病，糖尿病，中枢神经系统疾病，遗传疾病和过度增殖性疾病。
-
公开(公告)号：US07550423B2
公开(公告)日：2009-06-23
申请号：US10712081
申请日：2003-11-13
申请人： David H. Coy , Barry Morgan , William Murphy
发明人： David H. Coy , Barry Morgan , William Murphy
CPC分类号： C07K14/6555
摘要： The invention features somatostatin antagonists having a D-amino acid at the second residue.
摘要翻译： 本发明具有在第二残基具有D-氨基酸的生长抑素拮抗剂。
-
公开(公告)号：US07368427B1
公开(公告)日：2008-05-06
申请号：US09856676
申请日：1999-12-07
申请人： Zheng Xin Dong , David H. Coy
发明人： Zheng Xin Dong , David H. Coy
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , Y02P20/55
摘要： The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
摘要翻译： 本发明涉及胰高血糖素样肽-1的肽类似物，其药学上可接受的盐，涉及使用这些类似物治疗哺乳动物的方法以及包含所述类似物的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
105 条记录 (耗时 0.032 秒)
